Fulgent Genetics (NASDAQ:FLGT) Issues FY 2026 Earnings Guidance

Fulgent Genetics (NASDAQ:FLGT) issued an update on its FY 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of -2.350–2.220 for the period, compared to the consensus estimate of -1.820. The company issued revenue guidance of $330.0 million-$340.0 million, compared to the consensus revenue estimate of $351.2 million.

Fulgent Genetics Stock Up 2.9%

Fulgent Genetics stock traded up $0.57 during trading hours on Thursday, reaching $20.21. 258,029 shares of the company’s stock were exchanged, compared to its average volume of 450,780. The firm’s 50 day simple moving average is $19.26 and its 200 day simple moving average is $19.32. Fulgent Genetics has a twelve month low of $13.46 and a twelve month high of $31.04. The firm has a market capitalization of $573.96 million, a PE ratio of -8.46 and a beta of 0.89.

Fulgent Genetics (NASDAQ:FLGT) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.12). Fulgent Genetics had a negative net margin of 23.04% and a negative return on equity of 3.24%. The business had revenue of $85.39 million during the quarter, compared to analyst estimates of $94.00 million. Fulgent Genetics has set its FY 2026 guidance at -2.350–2.220 EPS. Analysts anticipate that Fulgent Genetics will post -2.81 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on FLGT shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Fulgent Genetics in a research note on Monday, July 6th. Piper Sandler restated a “neutral” rating and issued a $15.00 price target (down from $30.00) on shares of Fulgent Genetics in a report on Tuesday, May 5th. Finally, Wall Street Zen raised shares of Fulgent Genetics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 30th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $27.00.

Insiders Place Their Bets

In other news, insider Hanlin Gao sold 1,688 shares of Fulgent Genetics stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $17.89, for a total transaction of $30,198.32. Following the completion of the transaction, the insider directly owned 990,374 shares in the company, valued at $17,717,790.86. This trade represents a 0.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Jian Xie sold 2,146 shares of the business’s stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $17.89, for a total transaction of $38,391.94. Following the sale, the chief operating officer directly owned 367,605 shares of the company’s stock, valued at approximately $6,576,453.45. The trade was a 0.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 5,980 shares of company stock valued at $106,360 in the last 90 days. 36.18% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Millennium Management LLC grew its holdings in Fulgent Genetics by 1.8% during the third quarter. Millennium Management LLC now owns 1,468,844 shares of the company’s stock worth $33,196,000 after buying an additional 26,582 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Fulgent Genetics by 1.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,179,254 shares of the company’s stock worth $26,651,000 after acquiring an additional 13,295 shares during the last quarter. RTW Investments LP purchased a new position in Fulgent Genetics during the 4th quarter worth $18,521,000. Geode Capital Management LLC grew its stake in shares of Fulgent Genetics by 1.3% in the 4th quarter. Geode Capital Management LLC now owns 508,224 shares of the company’s stock worth $13,353,000 after acquiring an additional 6,553 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Fulgent Genetics by 12.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 402,802 shares of the company’s stock worth $10,582,000 after acquiring an additional 43,521 shares in the last quarter. Hedge funds and other institutional investors own 48.06% of the company’s stock.

About Fulgent Genetics

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.